Context Therapeutics (NASDAQ:CNTX) Releases Earnings Results, Misses Expectations By $0.11 EPS

Context Therapeutics (NASDAQ:CNTX) issued its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11), Zacks reports.

Context Therapeutics Price Performance

Shares of NASDAQ CNTX traded down $0.14 during midday trading on Friday, reaching $1.95. The company’s stock had a trading volume of 339,093 shares, compared to its average volume of 295,287. The stock has a 50 day simple moving average of $2.09 and a 200-day simple moving average of $2.06. Context Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.75.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.